These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 28375534)

  • 21. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value.
    Tice JA; Kazi DS; Pearson SD
    JAMA Intern Med; 2016 Jan; 176(1):107-8. PubMed ID: 26662572
    [No Abstract]   [Full Text] [Related]  

  • 22. Reduction of cardiovascular risk with evolocumab (Repatha).
    Med Lett Drugs Ther; 2017 Apr; 59(1519):63-64. PubMed ID: 28419071
    [No Abstract]   [Full Text] [Related]  

  • 23. Indications of PCSK9 Inhibitors for Patients at High and Very High Cardiovascular Risk.
    Behr PEB; Moriguchi EH; Castro I; Bodanese LC; Dutra OP; Leães PE; Pimentel Filho P
    Arq Bras Cardiol; 2018 Jul; 111(1):104-108. PubMed ID: 30110052
    [No Abstract]   [Full Text] [Related]  

  • 24. Improvement in arterial stiffness after short-term treatment with PCSK9 inhibitors.
    Cicero AFG; Toth PP; Fogacci F; Virdis A; Borghi C
    Nutr Metab Cardiovasc Dis; 2019 May; 29(5):527-529. PubMed ID: 30954414
    [No Abstract]   [Full Text] [Related]  

  • 25. Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.
    Wójcik C
    Postgrad Med; 2017 Nov; 129(8):801-810. PubMed ID: 28879791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Up to date lipid lowering treatment].
    Paragh G; Karádi I
    Orv Hetil; 2016 Jul; 157(31):1219-23. PubMed ID: 27476517
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dyslipidaemia: The PCSK9 adventure - humanizing extreme LDL lowering.
    Shapiro MD; Fazio S
    Nat Rev Cardiol; 2017 Jun; 14(6):319-320. PubMed ID: 28470176
    [No Abstract]   [Full Text] [Related]  

  • 28. Intensive LDL lowering therapy for prevention of recurrent cardiovascular events: a word of caution.
    Simoons ML; Deckers JW
    Eur Heart J; 2016 Feb; 37(6):520-3. PubMed ID: 26537621
    [No Abstract]   [Full Text] [Related]  

  • 29. PCSK9 inhibitors in the prevention of cardiovascular disease.
    Latimer J; Batty JA; Neely RD; Kunadian V
    J Thromb Thrombolysis; 2016 Oct; 42(3):405-19. PubMed ID: 27095708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [PCSK9 inhibition--A new era in cholesterol treatment].
    Olsson A
    Lakartidningen; 2015 Feb; 112():. PubMed ID: 25689006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PCSK9 antibodies: A new class of lipid-lowering drugs.
    Gouni-Berthold I
    Atheroscler Suppl; 2015 May; 18():21-7. PubMed ID: 25936300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rescue therapy with PCSK9 inhibitors for patients with delayed diagnosis of heterozygous familial hypercholesterolemia: Redressing the balance of missed opportunities.
    Vuorio A; Watts GF; Kovanen PT
    J Clin Lipidol; 2016; 10(5):1278-9. PubMed ID: 27678448
    [No Abstract]   [Full Text] [Related]  

  • 33. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E; Salvetti M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Anti-PCSK9 antibodies in type 2 diabetes and secondary prevention of cardiovascular diseases].
    López-Miranda J; Pintó X
    Clin Investig Arterioscler; 2016 May; 28 Suppl 2():31-38. PubMed ID: 27888904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Inhibition of the protein PCSK9 is a promising target in the prevention of cardiovascular disease].
    Christiansen MK; Jensen HK
    Ugeskr Laeger; 2015 Mar; 177(11):. PubMed ID: 25786699
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
    Jetty V; Glueck CJ; Lee K; Goldenberg N; Prince M; Kumar A; Goldenberg M; Anand I; Wang P
    Vasc Health Risk Manag; 2017; 13():247-253. PubMed ID: 28740397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cholesterol, Cardiovascular Risk, Statins, PCSK9 Inhibitors, and the Future of LDL-C Lowering.
    Rodriguez F; Harrington RA
    JAMA; 2016 Nov; 316(19):1967-1968. PubMed ID: 27838727
    [No Abstract]   [Full Text] [Related]  

  • 38. Cardiovascular risk reduction: the future of cholesterol lowering drugs.
    Bou Malham S; Goldberg AC
    Curr Opin Pharmacol; 2016 Apr; 27():62-9. PubMed ID: 26939026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PCSK9-lowering RNAi contender clears first phase III trial.
    Mullard A
    Nat Rev Drug Discov; 2019 Sep; 18(10):737. PubMed ID: 31570849
    [No Abstract]   [Full Text] [Related]  

  • 40. Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy.
    Glueck CJ; Shah P; Goldenberg N; Prince M; Lee K; Jetty V; Kumar A; Goldenberg M; Wang P
    Lipids Health Dis; 2016 Mar; 15():55. PubMed ID: 26968977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.